Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation
DOI: https://doi.org/10.2147/dddt.s459658
IF: 4.3188
2024-05-14
Drug Design Development and Therapy
Abstract:Guoquan Chen, 1, &ast Jiale Chen, 1, &ast Qiang Zhao, 2 Yalan Zhu 1 1 Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People's Republic of China; 2 Department of Cardiology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yalan Zhu, Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People's Republic of China, Tel +86-0579-82552760, Email Objective: Atrial fibrillation (AF) is the most common abnormal heart rhythm in elderly patients. Rivaroxaban has been widely used for stroke prevention. The anticoagulant response to rivaroxaban increases with age, which may make elderly patients susceptible to adverse outcomes resulting from small differences in bioavailability between generic and brand products. Methods: We designed a cohort study of ≥ 65-year-old inpatients with AF. Sociodemographic and laboratory measures of qualified patients who received brand or generic rivaroxaban for at least 72 hours at the study hospital from January 2021 to June 2023 were collected retrospectively. The primary outcome was the incidence of bleeding. Results: A total of 1008 qualifying patients were included for analysis, with 626 (62.1%) receiving brand rivaroxaban and 382 (37.9%) receiving generic rivaroxaban. After propensity score matching and weighting to account for confounders, the odds ratios comparing brand vs generic rivaroxaban (95% confidence intervals) for the bleeding was 1.15 (0.72– 1.82). Results from subgroup analyses of patients with age ≥ 85, HAS-BLED score ≥ 3, containment of antiplatelet drugs, and female patients were consistent with the primary analysis. Conclusion: It provides evidence regarding the clinical safety outcome of generic rivaroxaban in the elderly AF population that may be particularly susceptible to adverse outcomes resulting from small allowable differences in pharmacokinetics. Keywords: bleeding, rivaroxaban, generic, brand, atrial fibrillation Generic medicine contains the same active substance(s) as brand/reference medicine and is bioequivalent to brand/reference medicine. Generally, generic medicine 1 is considered to be comparable to brand/reference medicine in dosage form, route of administration, and treatment characteristics. In the context of increasing global healthcare expenditure, generic medicine utilization is often encouraged as a cost-containment measure, which can be priced as low as 2–10% of pre-patent loss prices. 2 While the negative opinions about generic medicines by both professionals and the general public interfere with the acceptance of generic medicines in healthcare provision. 3 Atrial fibrillation (AF) is one of the most common cardiac arrhythmias in elderly patients. 4 Rational anticoagulation for stroke prevention is one of the pillars of AF management. 5 Direct oral anticoagulants (DOACs) are now recommended as first-line therapy by up-to-date guidelines. 6,7 Rivaroxaban 8 is a direct factor Xa inhibitor, targeting free and clot-bound coagulation factor Xa and blocking the common coagulation pathway. Despite a better safety profile than warfarin, 9 as more patients are being treated with rivaroxaban, the absolute number of bleeding events increases. 10 Advanced age 11 is a shared risk factor for both thromboembolic and bleeding events. Additionally, elderly patients frequently face challenges such as polypharmacy, poor medication adherence, impaired liver and kidney function, and increased risk of falls and undernutrition, 12–14 which make them more susceptible to suboptimal anticoagulation or excessive anticoagulation when receiving rivaroxaban treatment. Elderly subjects exhibited higher plasma concentrations, with mean AUC values being 41% higher in the elderly than in younger subjects. 15 When formulating an individualized anticoagulation regimen for elderly patients with AF, the consistency of safety and efficacy between brand and generic rivaroxaban has been a main clinical concern. Given the wide use of rivaroxaban, it is important to assess whether small allowable differences in bioavailability between brand and generic versions are associated with differences in clinical outcomes in the real world. Currently, no studies have been conducted to compare the clinical outcomes between generic and brand rivaroxaban. To that end, we designed this study of 65 years or older inpatients with AF to compare clinical -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal